Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00096
|
|||||
| Drug Name |
Trifluridine
|
|||||
| Synonyms |
1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; 2'-Deoxy-5-(trifluoromethyl)uridine; 2'-Deoxy-5-trifluoromethyluridine; 5-(Trifluoromethyl)-2'-deoxyuridine; 5-(Trifluoromethyl)deoxyuridine; 5-Trifluoro-2'-deoxythymidine; 5-Trifluoromethyl-2'-deoxyuridine; 5-Trifluoromethyl-2-deoxyuridine; 5-Trifluorothymidine; Alpha,alpha,alpha-Trifluorothymidine; CF3dUrd; F3DThd; F3T; F3TDR; Fluridine; HS-0007; TFDU; TRIFLUOROTHYMIDINE; Trifluoridine; Trifluoromethyldeoxyuridine; Trifluorothymine deoxyriboside; Trifluridina; Trifluridina [INN-Spanish]; Trifluridine (USP/INN);Viroptic, Trifluorothymidine, Trifluridine; Trifluridine [USAN:INN]; Trifluridinum; Trifluridinum [INN-Latin]; Virophta; Viroptic; Viroptic (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Herpes simplex virus infection [ICD11:1F00] | Approved | [1] | |||
| Therapeutic Class |
Antiviral Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H11F3N2O5
|
|||||
| Canonical SMILES |
C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
|
|||||
| InChI |
InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
|
|||||
| InChIKey |
VSQQQLOSPVPRAZ-RRKCRQDMSA-N
|
|||||
| CAS Number |
CAS 70-00-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 296.2 | Topological Polar Surface Area | 99.1 | ||
| Heavy Atom Count | 20 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-0.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103321204
,104023317
,104253375
,104311541
,118048237
,12014784
,12149237
,124757493
,124800643
,125164297
,126667216
,129521334
,131404691
,134223275
,134338045
,134971818
,135681084
,135692274
,136369804
,137000771
,137005241
,137213977
,144205964
,14751529
,14849367
,152058901
,160963778
,163835390
,170464911
,172092201
,172919625
,174483143
,175266936
,175612130
,176484794
,179116934
,24900027
,29225252
,46506192
,50054714
,56422883
,57323294
,626314
,77174799
,7847457
,7980831
,8139891
,8153936
,87560183
,93815015
|
|||||
| ChEBI ID |
CHEBI:75179
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | CNT1 | Transporter Info | Concentrative nucleoside transporter 1 | Substrate | [2] | |
| ENT1 | Transporter Info | Equilibrative nucleoside transporter 1 | Substrate | [2] | ||
| ENT2 | Transporter Info | Equilibrative nucleoside transporter 2 | Substrate | [2] | ||
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Trifluridine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Lonsurf, INN-trifluridine/tipiracil. | |||||
| 3 | Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther. 2000 Sep;294(3):844-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.